^
Association details:
| Biomarker: | HER-2 G778_S779insCPG |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
Published date:
07/31/2020
Excerpt:
Patient 4 was a 65 year-old female never-smoker who was diagnosed with advanced lung adenocarcinoma...The result of NGS of re-biopsy tissue revealed HER2 exon 20 insertion mutation (p.G778_S779insCPG) (Figures 1A,C)...Then, the patient received pyrotinib plus bevacizumab as the third-line therapy...One month later, she achieved partial response (PR)...
DOI:
10.3389/fonc.2020.01162
